Electronically addressable DNA assembly - the ability to routinely synthesize entire genomes is one of the great remaining technical aspirations of the synthetic biology revolution
Ended Project Grant Awarded Last action
- Award ID
- R43GM150322
- Recipient
-
Avery Bio Corporation UEI FRN3WHBZKNA5
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $275,766
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
The complexity of designing the annealing reactions used by existing assembly workflows is a fundamental barrier to genome-scale DNA production. There is a practical limit to the number of distinct sequences which can reliably self-assemble into the desired construct in a single step, and traditional assembly reactions are typically limited in scale to tens or hundreds of oligonucleotides. Current parallel synthesis technologies can generate pools of over 1 million oligonucleotides, which is entirely inadequate for a genome-scale construction, yet far more complex than can be reliably assembled in a single reaction. Despite substantial interest in improving oligonucleotide synthesis throughput, such technologies cannot be leveraged fully without accompanying means of guiding their assembly. We have made advancements to generate oligonucleotides at a throughput 100× any published system. The proposed studies work to translate this advance (up to 100× enhancement) to the throughput of gene assembly. The underlying concept is to perform DNA synthesis on a substrate capable of controlling the localization of the oligonucleotides during their subsequent assembly. If successful, the approach would address a fundamental scalability mismatch between oligonucleotide synthesis and assembly, enabling a new generation of gene synthesis technologies capable of exceeding the scale of the human genome with a single synthesis run. This project may lead to a 100X parallelization increase and 100X cost decrease, and potentially increase assembly accuracy.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $275,766 |
Quick answers
Who received award R43GM150322?
R43GM150322 was awarded to Avery Bio Corporation by National Institute of General Medical Sciences (National Institutes of Health) on April 1, 2023.
How much is award R43GM150322 worth?
$275,766 has been obligated on R43GM150322.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award